# Perioperative Treatment of High-risk Resectable CCA With HAIC Plus A+T: Neobrave CCA

> **NCT06739252** · PHASE2 · TERMINATED · sponsor: **Peking University** · enrollment: 1 (actual)

## Conditions studied

- Intrahepatic Cholangiocarcinoma (Icc)
- Perihilar Cholangiocarcinoma

## Interventions

- **COMBINATION_PRODUCT:** Gemcitabine Oxaliplatin and 5FU

## Key facts

- **NCT ID:** NCT06739252
- **Lead sponsor:** Peking University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-12-31
- **Primary completion:** 2025-12-22
- **Final completion:** 2025-12-22
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Difficulty of participants enrollment
- **Last updated:** 2026-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06739252

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06739252, "Perioperative Treatment of High-risk Resectable CCA With HAIC Plus A+T: Neobrave CCA". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06739252. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*